このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Humanigen は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

OTCPK:HGEN.Q - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2023	2	-54	-64	-64	N/A
12/31/2022	3	-71	-77	-77	N/A
9/30/2022	3	-109	-94	-94	N/A
6/30/2022	4	-152	-125	-125	N/A
3/31/2022	4	-192	-168	-168	N/A
12/31/2021	4	-237	-184	-184	N/A
9/30/2021	3	-235	-175	-175	N/A
6/30/2021	2	-199	-151	-151	N/A
3/31/2021	1	-153	-105	-105	N/A
12/31/2020	0	-90	-70	-70	N/A
9/30/2020	N/A	-59	-47	-47	N/A
6/30/2020	N/A	-31	-24	-24	N/A
3/31/2020	N/A	-10	-4	-4	N/A
12/31/2019	N/A	-10	-4	-4	N/A
9/30/2019	N/A	-10	-5	-5	N/A
6/30/2019	N/A	-10	-5	-5	N/A
3/31/2019	N/A	-9	-5	-5	N/A
12/31/2018	N/A	-12	-6	-6	N/A
9/30/2018	N/A	-13	-7	-7	N/A
6/30/2018	N/A	-18	-10	-10	N/A
3/31/2018	N/A	-22	-12	-12	N/A
12/31/2017	N/A	-22	-14	-14	N/A
9/30/2017	N/A	-24	-15	-15	N/A
6/30/2017	N/A	-21	-20	-20	N/A
3/31/2017	N/A	-27	-23	-23	N/A
12/31/2016	N/A	-27	N/A	-21	N/A
9/30/2016	N/A	-35	N/A	-26	N/A
6/30/2016	N/A	-37	N/A	-23	N/A
3/31/2016	N/A	-31	N/A	-22	N/A
12/31/2015	N/A	-35	N/A	-29	N/A
9/30/2015	N/A	-32	N/A	-28	N/A
6/30/2015	N/A	-33	N/A	-30	N/A
3/31/2015	N/A	-37	N/A	-34	N/A
12/31/2014	N/A	-38	N/A	-36	N/A
9/30/2014	0	-39	N/A	-39	N/A
6/30/2014	0	-42	N/A	-39	N/A
3/31/2014	0	-44	N/A	-42	N/A
12/31/2013	0	-42	N/A	-39	N/A
9/30/2013	0	-43	N/A	-37	N/A

アナリストによる今後の成長予測

収入対貯蓄率: HGEN.Qの予測収益成長が貯蓄率 ( 2.4% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: HGEN.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: HGEN.Qの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: HGEN.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: HGEN.Qの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: HGEN.Qの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Humanigen 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2025

Consensus forecasts updated

Price target decreased to US$4.75

Consensus revenue estimates increase by 34%

Consensus revenue estimates fall by 58%

No longer forecast to breakeven

Recent updates

Humanigen, Inc. Filed for Bankruptcy

Levi & Korsinsky, LLP and Pomerantz LLP Announce A Proposed Settlement for the in Re Humanigen, Inc. Securities Litigation

The Nasdaq Stock Market to Delist the Common Stock of Humanigen

Humanigen, Inc. Announces Resignation of Edward Jordan as Chief Commercial Officer

Humanigen, Inc.(OTCPK:HGEN) dropped from S&P TMI Index

Humanigen, Inc.(OTCPK:HGEN) dropped from NASDAQ Composite Index

Humanigen, Inc. Announces Board Changes

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.035 loss per share (vs US$0.32 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.75

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Humanigen Receives Non-Compliance Letter from Nasdaq

Bernstein Liebhard LLP Announces Class Action Lawsuit Against Humanigen, Inc

Humanigen, Inc. Announces Executive Changes

Humanigen, Inc. Announces Resignation Adrian Kilcoyne as Chief Medical Officer, Effective September 28, 2022

Pomerantz LLP Announces the Filing of a Class Action Against Humanigen, Inc. and Certain of its Officers

Consensus revenue estimates increase by 34%

First half 2022 earnings released

Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M

Consensus revenue estimates fall by 58%

No longer forecast to breakeven

Price target decreased to US$8.70

Humanigen, Inc. Receives Preliminary Topline Data from NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B

Humanigen plunges 57% as trial for COVID-19 therapy fails

Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy

Consensus revenue estimates increase by 19%

Humanigen, Inc., Annual General Meeting, Jun 09, 2022

Chairman & CEO recently bought US$94k worth of stock

Forecast to breakeven in 2023

Consensus revenue estimates increase by 12%

Forecast to breakeven in 2023

Humanigen Launches Managed Access Program for Lenzilumab

Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T

Humanigen, Inc. Announces Target Enrollment in Phase 2/3 Activ-5/Bet-B Trial of Lenzilumab for the Treatment of Covid-19 Has Been Achieved

Humanigen, Inc. Announces A Manuscript Detailing the Results of an Analysis of CRP Levels from the Live-Air Phase 3 Study

Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

FDA Declines Humanigen’s Emergency Use Authorization Request for Lenzilumab in Hospitalized COVID-19 Patients

Price target decreased to US$28.33

Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Chairman & CEO recently sold US$1.7m worth of stock

Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency

Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.

Humanigen Submits Application to FDA for Emergency Use Authorization for lenzilumab in Covid-19

Humanigen submits lenzilumab COVID-19 EUA application to FDA

Eversana Advances Commercialization Readiness as Humanigen Announces Publication of Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab™ in Newly Hospitalized Covid-19 Patients

Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Price target increased to US$32.14

Humanigen, Inc., Annual General Meeting, Jun 17, 2021

Humanigen, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

Earnings beat expectations

Chief Accounting & Administrative Officer, Corporate Secretary and Treasurer has left the company

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

New 90-day high: US$23.83

Humanigen, Inc. Announces Executive Changes

Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing

Humanigen, Inc. Completes Enrollment in Phase 3 Study of Lenzilumab

Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19

Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational Covid-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study

Humanigen, Inc Announces the Addition of BARDA and Expansion of CRADA with the U.S. Government to Develop Lenzilumab for COVID-19

Humanigen, Inc. and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19

Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment

Humanigen, Inc. Announces Retirement of Robert G. Savage from the Board of Directors

We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Humanigen secures new U.S. patent for lenzilumab

Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme